Next Article in Journal
Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery
Previous Article in Journal
Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 5
Issue 9
10.3390/jcm5090081
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to J. Clin. Med. 2015, 4(10), 1890-1907.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890–1907

by
Shigeshi Ono
,
Stella Lam
,
Makoto Nagahara
and
Dave S. B. Hoon
*
Department of Molecular Oncology, John Wayne Cancer Institute, Providence Saint John’s Health Center, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2016, 5(9), 81; https://doi.org/10.3390/jcm5090081
Submission received: 31 August 2016 / Revised: 31 August 2016 / Accepted: 31 August 2016 / Published: 12 September 2016
Versions Notes
The authors wish to make the following corrections to this paper [1]:
Table
Table 4. Summary of microarrays for cmiRNA.
Table 4. Summary of microarrays for cmiRNA.
AssayRequired Input (ng)Probe Content
Affymetrix GeneChip miRNA Arrays 4.0130miRBase v.20
Agilent oligonucleotides microarrays100miRBase v.21
Exiqon miRCURY LNA microRNA arrays30miRBase v.19
µParaflo®Microfluidic Biochip Technology1000miRBase v.21
3D-Gene®2000miRBase v.21
should be replaced with
Table
Table 4. Summary of microarrays for cmiRNA.
Table 4. Summary of microarrays for cmiRNA.
AssayRequired Input (ng)Probe Content
Affymetrix GeneChip miRNA Arrays 4.0130miRBase v.20
Agilent oligonucleotides microarrays100miRBase v.21
Exiqon miRCURY LNA microRNA arrays30miRBase v.19
µParaflo®Microfluidic Biochip Technology1000miRBase v.21
3D-Gene®250miRBase v.21
The authors apologize for any inconvenience caused to the readers by these changes.

Reference

  1. Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890–1907. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890–1907. J. Clin. Med. 2016, 5, 81. https://doi.org/10.3390/jcm5090081

AMA Style

Ono S, Lam S, Nagahara M, Hoon DSB. Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890–1907. Journal of Clinical Medicine. 2016; 5(9):81. https://doi.org/10.3390/jcm5090081

Chicago/Turabian Style

Ono, Shigeshi, Stella Lam, Makoto Nagahara, and Dave S. B. Hoon. 2016. "Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890–1907" Journal of Clinical Medicine 5, no. 9: 81. https://doi.org/10.3390/jcm5090081

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop